Dublin, Sept. 27, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/plrj5k/randd)
has announced the addition of the "R&D
Productivity - The State of Research and Development in the
Biopharmaceutical Industry" report to their offering.
As blockbusters go off patent and the pool of marketed products
supporting pharmaceutical Research & Development (R&D)
decline, questions about the future of R&D in the
pharmaceutical and biotech industry arise. Where will funding come
from? Is spend decreasing? If spend is decreasing, what impact is
this having on R&D? What can be done to encourage innovation in
the biotech and pharmaceutical industry? Is the biotech model of
R&D better for innovation than the traditional pharmaceutical
model?
Gauging the overall growth of R&D in the pharmaceutical and
biotech industry proves challenging in regards to stipulating the
appropriate definition of variables by which this is measured.
Public companies may release overall expenses, yet allocations to
specific products or franchises may be more difficult to assess. On
a related note, information may be available about specific
research projects and molecules under development, yet tying those
back to the overall R&D expenses can also be challenging. To
that end, we are focused on general estimations in this report
which address a high level analysis of the overall industry and a
basic formulaic approach to understanding growth and productivity
within R&D. The methods used for assessing these variables are
supported by literature in the field.
Research
& Development (R&D) in the Pharmaceutical and Biotech
Industry has experienced a major shift from the blockbuster era of
the last decade. Pharmaceutical manufacturers are operating with
thinner margins and smaller pipelines, the success rates of early
stage research projects have decreased, and overall the complexity
of efficient and productive R&D in the pharmaceutical industry
has increased. This report provides an overview of the current
situation in pharmaceutical and biotech R&D.
Key Reasons to Purchase
- Understand the current state of R&D in the bio-pharmaceutical industry and the key issues that are affecting companys' efforts
- Assess the strategies being used to strengthen R&D productivity and relate them to what is taking place within your organization
- Evaluate how the top pharmaceutical and biotech companies have structured their pipeline
- Analyze the trends being seen in R&D spend and how different forms of collaboration could support a stronger R&D organization
- Examine the R&D landscape and identify the key disease areas seeing the greatest activity
- Benefit from CBR's insights & case study analysis to support a better understanding of different influencers of R&D productivity and the strategies which can be used within your organization
Key Topics Covered:
1. Executive Summary
2. Current Picture of Research and Development
- Key issues affecting the industry's R&D efforts
- A review of the industry pipeline
- Pipeline by phase of development
- Pipeline by therapeutic area and, more specifically, indication
- Pipeline's molecule mix
- Do traditional pharmaceutical companies still exist?
- Approvals by year and by sponsor (Established vs. Emerging companies)
- Trends in R&D spend
- Review of Top companies R&D spend
- Probability of success rates on several levels: overall clinical approval, phase transition, and therapeutic area
3. R&D Productivity
- Components of R&D productivity: efficiency and effectiveness
- Variables that influence productivity
- Industry efforts to improve productivity
- CROs take on a greater role
- What roles do Physicians, Payers, Patients, and Shareholders play in R&D?
- Featuring Biotech Incubators
4. Company Pipeline Snapshots (15 companies included)
- Pipeline views on a company by company basis.
- Trends in R&D spend
5. References
For more information visit http://www.researchandmarkets.com/research/plrj5k/randd
Research and
Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Pharmaceuticals